Private benefit of β-lactamase dictates selection dynamics of combination antibiotic treatment
Open Access
- 27 September 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Abstract
β-lactam antibiotics have been prescribed for most bacterial infections since their discovery. However, resistance to β-lactams, mediated by β-lactamase (Bla) enzymes such as extended spectrum β-lactamases (ESBLs), has become widespread. Bla inhibitors can restore the efficacy of β-lactams against resistant bacteria, an approach which preserves existing antibiotics despite declining industry investment. However, the effects of combination treatment on selection for β-lactam resistance are not well understood. Bla production confers both private benefits for resistant cells and public benefits which faster-growing sensitive cells can also exploit. These benefits may be differentially impacted by Bla inhibitors, leading to non-intuitive selection dynamics. In this study, we demonstrate strain-to-strain variation in effective combination doses, with complex growth dynamics in mixed populations. Using modeling, we derive a criterion for the selection outcome of combination treatment, dependent on the burden and effective private benefit of Bla production. We then use engineered strains and natural isolates to show that strong private benefits of Bla are associated with increased selection for resistance. Finally, we demonstrate that this parameter can be coarsely estimated using high-throughput phenotyping of clonal populations. Our analysis shows that quantifying the phenotypic responses of bacteria to combination treatment can facilitate resistance-minimizing optimization of treatment.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01AI125604, R01GM098642, R01EB031869)
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | National Institutes of Health
- United States - Israel Binational Science Foundation (2021192)
- National Science Foundation (DGE 1644868)
This publication has 72 references indexed in Scilit:
- Three Decades of β-Lactamase InhibitorsClinical Microbiology Reviews, 2010
- Emergence of Extended‐Spectrum β‐Lactamase–ProducingEscherichiacoliin Community Hospitals throughout North Carolina: A Harbinger of a Wider Problem in the United States?Clinical Infectious Diseases, 2009
- Snowdrift game dynamics and facultative cheating in yeastNature, 2009
- Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative BacilliAntimicrobial Agents and Chemotherapy, 2008
- Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulationJournal of Antimicrobial Chemotherapy, 2004
- Lung Infections Associated with Cystic FibrosisClinical Microbiology Reviews, 2002
- Appropriate prescribing of oral beta-lactam antibiotics.2000
- Penetration of β-lactamase inhibitors into the periplasm of Gram-negative bacteriaFEMS Microbiology Letters, 1999
- Outer membrane permeability of β-lactamase inhibitors inPseudomonas aeruginosaFEMS Microbiology Letters, 1995
- Recurrence rate of streptococcal pharyngitis related to oral penicillinThe Journal of Pediatrics, 1969